Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 228

1.

Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.

Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG.

J Bone Miner Res. 2017 Mar 9. doi: 10.1002/jbmr.3119. [Epub ahead of print]

PMID:
28277603
2.

Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases.

Lewiecki EM, Bilezikian JP, Bukata SV, Camacho P, Clarke BL, McClung MR, Miller PD, Shepherd J.

J Clin Densitom. 2017 Feb 6. pii: S1094-6950(16)30287-6. doi: 10.1016/j.jocd.2017.01.001. [Epub ahead of print] Review.

3.

Observations following discontinuation of long-term denosumab therapy.

McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM.

Osteoporos Int. 2017 Jan 31. doi: 10.1007/s00198-017-3919-1. [Epub ahead of print]

PMID:
28144701
4.

Romosozumab for the treatment of osteoporosis.

Bandeira L, Lewiecki EM, Bilezikian JP.

Expert Opin Biol Ther. 2017 Feb;17(2):255-263. doi: 10.1080/14712598.2017.1280455.

PMID:
28064540
5.

Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.

Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST.

Osteoporos Int. 2017 Apr;28(4):1355-1363. doi: 10.1007/s00198-016-3886-y.

PMID:
28058444
6.

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.

Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan De Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S.

J Bone Miner Res. 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039.

PMID:
27864889
7.

Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint.

Miller CG, Bogado CC, Nino AJ, Northcutt AR, Yu HJ, Lewiecki EM, Paul G, Cobitz AR, Wooddell MJ, Bilezikian JP, Fitzpatrick LA.

J Clin Densitom. 2016 Oct;19(4):485-491. doi: 10.1016/j.jocd.2016.02.003.

PMID:
27052635
8.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A.

N Engl J Med. 2016 Oct 20;375(16):1532-1543.

PMID:
27641143
9.

High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women.

DeFina LF, Leonard D, Willis BL, Barlow CE, Finley CE, Jenkins MR, Pence BC, Zhang Y, Chyu MC, Lewiecki EM, Shen CL.

J Womens Health (Larchmt). 2016 Oct;25(10):1073-1080.

PMID:
27749191
10.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB.

Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42.

PMID:
27662240
11.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB.

Endocr Pract. 2016 Sep;22(9):1111-8. doi: 10.4158/EP161435.ESGL.

PMID:
27643923
12.

Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP.

Osteoporos Int. 2017 Jan;28(1):1-19. doi: 10.1007/s00198-016-3716-2. Review.

13.

Telementoring: a novel approach to reducing the osteoporosis treatment gap.

Lewiecki EM, Boyle JF, Arora S, Bouchonville MF 2nd, Chafey DH.

Osteoporos Int. 2017 Jan;28(1):407-411. doi: 10.1007/s00198-016-3708-2.

PMID:
27439373
14.

A Comprehensive Fracture Prevention Strategy in Older Adults: The European Union Geriatric Medicine Society (EUGMS) Statement.

Blain H, Masud T, Dargent-Molina P, Martin FC, Rosendahl E, van der Velde N, Bousquet J, Benetos A, Cooper C, Kanis JA, Reginster JY, Rizzoli R, Cortet B, Barbagallo M, Dreinhöfer KE, Vellas B, Maggi S, Strandberg T; EUGMS Falls and Fracture Interest Group.; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Osteoporosis Research and Information Group (GRIO), and International osteoporosis Foundation (IOF)..

J Nutr Health Aging. 2016;20(6):647-52. doi: 10.1007/s12603-016-0741-y.

15.

Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.

Bandeira L, Lewiecki EM, Bilezikian JP.

Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):681-9. doi: 10.1080/17425255.2016.1175436. Review.

PMID:
27070719
16.

Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance.

Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD; International Society for Clinical Densitometry..

J Clin Densitom. 2016 Apr-Jun;19(2):127-40. doi: 10.1016/j.jocd.2016.03.003.

PMID:
27020004
17.

What we don't know about osteoporosis.

Lewiecki EM, Binkley N.

J Endocrinol Invest. 2016 May;39(5):491-3. doi: 10.1007/s40618-016-0442-8. No abstract available.

PMID:
26902997
18.

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA.

J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181.

19.

A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.

Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao SD, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Alam J, Ruff VA, Gallagher ER, Taylor KA.

J Bone Miner Res. 2016 Jul;31(7):1429-39. doi: 10.1002/jbmr.2804.

PMID:
26841258
20.

Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease.

Lewiecki EM, Baron R, Bilezikian JP, Gagel RE, Leonard MB, Leslie WD, McClung MR, Miller PD.

J Clin Densitom. 2016 Jan-Mar;19(1):102-16. doi: 10.1016/j.jocd.2015.11.003.

PMID:
26750746

Supplemental Content

Loading ...
Support Center